Ру En
IT IS THE RIGHT TIME TO MANUFACTURE AFFORDABLE AND QUALITATIVE PHARMACEUTICAL PRODUCTS!
JOINT-STOCK COMPANY
Pharmaceutical Import, Export
Since 1991
Vital medicines should be accessible to everyone!
Apazov A.D., president of Pharmimex JSC
Tilda Publishing

  • SUPPLY

    JSC Pharmimex is a leading supplier of medicines for government budget purchases.

  • PRODUCTION

    New Full-Cycle Blood Product Manufacturing Plant

    Featuring a state-of-the-art plasma storage facility with a capacity of 600 tons. Plasma is stored at -35°C.

  • IMPORT SUBSTITUTION

    90% of the immunoglobulins currently imported from abroad will be manufactured in Russia.

Since 2000, JSC Pharmimex has been providing medications for the treatment of rare diseases, offering assistance to patients whose treatments were previously unavailable:

Hemophilia, Gaucher Disease, Fabry Disease, Various Types of Mucopolysaccharidosis, Spinal Muscular Atrophy, Duchenne Muscular Dystrophy, Acid Lysosomal Lipase Deficiency, Batten Disease, T-Cell Lymphoma, and Others.
COMPANY INFRASTRUCTURE
89 Regions
of Russia and Baikonur
Robust Logistics Network
17 Regions
Own Warehousing Facilities
42 000 m²
Warehouse Area
-86 °C
Controlled and validated adherence to the cold chain throughout storage and delivery
13
Subsidiaries, Trading Offices, and Branches
2805 м³
Refrigeration Chambers
JSC Pharmimex initiated the establishment of a modern facility in Russia for the production of human blood plasma-derived medications.
  • 600
    Tons of plasma per year. Processing at the new full-cycle plant in the Ryazan region starting in 2025.
  • 10
    Plasma collection centers for fractionation will be established in regions across Russia.
  • 600
    600 tons of blood plasma can be stored at -35°C in a modern plasma storage facility.
PHARMIMEX IN THE RANKINGS OF THE LARGEST NATIONAL COMPANIES


# 3 in Budget Sales Volume in the Ranking of Russian Distributors (IQVIA, 2024)


According to the voluntary certification system "Registry of Highly Effective Organizations of the Russian Economy," JSC Pharmimex is financially stable, equipped with high-tech production facilities, demonstrates high performance in its management systems, efficiently utilizes material, technical, and labor resources, significantly influences the industry economy, and holds a justified right to participate in the implementation of the State Healthcare Development Program, as well as the programs and projects aimed at developing the pharmaceutical and medical industries of the Russian Federation.
Pharmaceutical Activity Licenses

According to the license annex, the Company is authorized to engage in:


  1. Wholesale trade of pharmaceutical products for medical use.
  2. Storage of pharmaceutical products for medical use.
  3. Transportation of pharmaceutical products for medical use.
  4. Activities related to the circulation of narcotic drugs, psychotropic substances, and their precursors.

220 Retail Pharmacy Locations:


  1. Storage of pharmaceutical products for medical use.
  2. Transportation of pharmaceutical products for medical use.
  3. Retail trade of pharmaceutical products for medical use.
  4. Dispensing of pharmaceutical products for medical use.
17 Licensed Warehouses in the
Regions of the Russian Federation
INFORMATION DISCLOSURE
In accordance with the public offer agreement concluded between JSC "Pharmaceutical Import, Export" (JSC "Pharmimex") and Limited Liability Company "Interfax – Corporate Information Disclosure Center" (LLC "Interfax-CRKI"), accredited to conduct information disclosure activities regarding securities and other financial instruments based on the decision of the Bank of Russia dated October 27, 2016, No. RB-52-5/1557,
LLC "Interfax-CRKI" publishes messages in the Interfax-CRKI News Feed containing information that the Company is obliged to disclose by publishing it in the News Feed and on a web page in accordance with the legislation of the Russian Federation and the regulatory legal acts of the Bank of Russia (hereinafter referred to as "Messages"), as well as other information that the Company is obliged to disclose on the web page in accordance with the legislation of the Russian Federation and the regulatory legal acts of the Bank of Russia. The Company gains access to the Interfax-CRKI Information Disclosure System, which allows for the publication of Messages and other information in the News Feed and on the web page provided by Interfax-CRKI.

WE ACT WITH INTEGRITY AND TRANSPARENCY

To ensure that the company's operations comply with legislation and ethical business standards, JSC Pharmimex fosters a strong corporate culture and has implemented an actively functioning compliance system.

JSC Pharmimex Supports a Number of Initiatives


Фонд «Круг добра»
кругдобра.рф
© 2024 All rights reserved